Key result
Transplanted allogeneic cardiac progenitor cells significantly improved left ventricular ejection fraction (49% vs 42%) and reduced scar size in a rat myocardial infarction model compared to vehicle.
Why the study?
The mechanism underlying the beneficial effects of allogenic cell-based therapies remains unclear despite promising results in clinical studies.
Does intramyocardial injection of allogeneic cardiac progenitor cells improve cardiac function and stimulate immunomodulatory responses in a rat myocardial infarction model?
Does intramyocardial injection of allogeneic cardiac progenitor cells improve cardiac function and stimulate immunomodulatory responses in a rat myocardial infarction model?
Allogeneic cardiac progenitor cells improve post-MI cardiac function and reduce scar size in rats by secreting GDF15, which promotes an immunomodulatory response involving T-regulatory cells and M2 macrophages.
Hypothesis-generating in rat MI; leaves open translation of allogeneic CPCs to human trials.
BACKGROUND: Despite promising results in clinical studies, the mechanism for the beneficial effects of allogenic cell-based therapies remains unclear. Macrophages are not only critical mediators of inflammation but also critical players in cardiac remodeling. We hypothesized that transplanted allogenic rat cardiac progenitor cells (rCPCs) augment T-regulatory cells which ultimately promote proliferation of M2 like macrophages by an as-yet undefined mechanism. METHODS AND RESULTS: To test this hypothesis, we used crossover rat strains for exploring the mechanism of myocardial repair by allogenic CPCs. Human CPCs (hCPCs) were isolated from adult patients undergoing coronary artery bypass grafting, and rat CPCs (rCPCs) were isolated from male Wistar-Kyoto (WKY) rat hearts. Allogenic rCPCs suppressed the proliferation of T-cells observed in mixed lymphocyte reactions in vitro. Transplanted syngeneic or allogeneic rCPCs significantly increased cardiac function in a rat myocardial infarct (MI) model, whereas xenogeneic CPCs did not. Allogeneic rCPCs stimulated immunomodulatory responses by specifically increasing T-regulatory cells and M2 polarization, while maintaining their cardiac recovery potential and safety profile. Mechanistically, we confirmed the inactivation of NF-kB in Treg cells and increased M2 macrophages in the myocardium after MI by transplanted CPCs derived GDF15 and it's uptake by CD48 receptor on immune cells. CONCLUSION: Collectively, these findings strongly support the active immunomodulatory properties and robust therapeutic potential of allogenic CPCs in post-MI cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Mishra et al. (2022) studied Myocardial Infarction. Allogeneic rat cardiac progenitor cells (rCPCs) vs. IMDM (vehicle control) was evaluated on Left ventricular ejection fraction (LVEF) at 28 days (p=<0.05). Transplanted allogeneic cardiac progenitor cells significantly improved left ventricular ejection fraction (49% vs 42%) and reduced scar size in a rat myocardial infarction model compared to vehicle.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: